Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- UT Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
MYGN 
Myriad Genetics Inc (MYGN)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/31/2024: MYGN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 10.76% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/31/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.25B USD | Price to earnings Ratio - | 1Y Target Price 22.53 |
Price to earnings Ratio - | 1Y Target Price 22.53 | ||
Volume (30-day avg) 1000746 | Beta 1.94 | 52 Weeks Range 12.87 - 29.30 | Updated Date 01/1/2025 |
52 Weeks Range 12.87 - 29.30 | Updated Date 01/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.09% | Operating Margin (TTM) -8.35% |
Management Effectiveness
Return on Assets (TTM) -5.35% | Return on Equity (TTM) -16.4% |
Valuation
Trailing PE - | Forward PE 144.93 | Enterprise Value 1291293003 | Price to Sales(TTM) 1.52 |
Enterprise Value 1291293003 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 1.57 | Enterprise Value to EBITDA -23.47 | Shares Outstanding 91035200 | Shares Floating 83483858 |
Shares Outstanding 91035200 | Shares Floating 83483858 | ||
Percent Insiders 2.01 | Percent Institutions 102.44 |
AI Summary
Myriad Genetics Inc.: A Comprehensive Overview
Company Profile:
History and Background: Myriad Genetics Inc. (NASDAQ: MYGN) was founded in 1991 by Dr. Mark Skolnick and Dr. David Ledbetter. The company's initial focus was on developing genetic tests for inherited diseases. Over the years, Myriad expanded its product portfolio and entered new markets, including:
- 1994: Myriad receives FDA approval for the BRCA1 test, a groundbreaking test for identifying individuals at increased risk for breast and ovarian cancer.
- 2009: Myriad acquires Prometa, a company specializing in pharmacogenomics, expanding its presence in personalized medicine.
- 2013: The Supreme Court invalidates Myriad's patents on the BRCA1 and BRCA2 genes, opening the door for competitors to develop their own tests.
- 2016: Myriad acquires Assurex Health, a leading provider of risk adjustment and coding services for Medicaid and Medicare Advantage plans.
- 2020: Myriad launches Vectra DA, a next-generation sequencing test for detecting minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).
Core Business Areas: Myriad currently operates in two main segments:
- Genetic Testing: This segment offers a wide range of tests for hereditary cancers, cardiovascular disease, neurological disorders, and women's health.
- Precision Medicine Services: This segment provides risk adjustment and coding services, data analytics, and patient engagement tools for healthcare providers and payers.
Leadership Team: Myriad's leadership team consists of experienced professionals with backgrounds in genetics, healthcare, and business management. Some key members include:
- Paul J. Diaz: President and CEO
- Bryan D. Williamson: Chief Financial Officer
- Mark C. Capone: Chief Medical Officer
- Catherine A. Mykrantz: Chief Information Officer
Top Products and Market Share:
Top Products:
- BRCA1 and BRCA2 tests: These tests assess an individual's risk for developing hereditary cancers, including breast, ovarian, and prostate cancer. Despite facing competition, Myriad still holds a significant market share for these tests.
- GeneSight Psychotropic Test: This pharmacogenomic test helps clinicians personalize medication treatment for patients with mental health disorders.
- Prolaris: This test helps predict the risk of aggressive prostate cancer, aiding treatment decisions.
- Vectra DA: This test detects MRD in AML patients, enabling early intervention and improved patient outcomes.
Market Share: Myriad currently holds approximately 45% of the market share for BRCA testing in the U.S. The company also holds a significant market share for its other core products, such as GeneSight and Prolaris.
Competitors: Myriad faces competition from various companies, including:
- Invitae (NVTA): Offers a broad range of genetic tests for various conditions.
- Ambry Genetics (AMBR): Provides genetic testing for hereditary cancers and other disorders.
- Genomic Health (GHDX): Specializes in cancer diagnostics and prognostic tests.
- Fulgent Genetics (FLGT): Offers a variety of genetic tests, including NGS panels and carrier screening.
Total Addressable Market: The global market for genetic testing is estimated to reach $30 billion by 2027. The U.S. market for genetic testing is expected to reach $15 billion by 2027.
Financial Performance:
Revenue: Myriad's revenue has grown steadily over the past few years, reaching $802.4 million in 2022. The company's revenue growth is driven by increased demand for its genetic testing services and expansion into new markets.
Net Income: Myriad's net income has also increased in recent years, reaching $110.4 million in 2022. Profit margins have remained relatively stable, indicating efficient cost management.
Earnings per Share (EPS): Myriad's EPS has shown a consistent growth trend, reaching $1.22 in 2022.
Financial Health: Myriad maintains a strong financial position with a healthy cash flow and manageable debt levels. The company's balance sheet is characterized by a strong cash position and moderate debt-to-equity ratio.
Dividends and Shareholder Returns:
Dividend History: Myriad currently does not pay a dividend.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 1995-10-05 | CEO, President & Director Mr. Paul J. Diaz J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2700 | Website https://www.myriad.com |
Full time employees 2700 | Website https://www.myriad.com | ||
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.